Advertisement

Neuropharmacology of Genus Hypericum: Hypericin and Hyperforin

  • Amritpal Singh Saroya
  • Jaswinder Singh
Chapter

Abstract

H. perforatum is known by various names including Amber touch-and-heal, balm-of-warrior’s wound, devil’s scourge, god’s wonder plant, Klamath weed, goatweed, perforate St John’s wort, rosin rose, touch and heal and witcher’s herb. However, St John’s wort is widely and popularly used common name of H. perforatum (Upton 1997). The word St John’s wort is given to plant because it was harvested on the occasion of St John’s day, which falls on 24th of the June (Gunther 1968).

References

  1. Bach-Rojecky L, Kalodjera Z, Samarzija I. The antidepressant activity of Hypericum perforatum L. measured by two experimental methods on mice. Acta Pharma. 2004;54:157–62.Google Scholar
  2. Baureithel KH, Berger Buter K, Engesser A, Bukard W, Schaffner W. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Act Helvetiae. 1997;72:153–7.CrossRefGoogle Scholar
  3. Beijamini V, Andreatini R. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol Res. 2003;48:199–207.CrossRefPubMedGoogle Scholar
  4. Berghoefer R, Hoelzl J. Bioflavonoids in Hypericum perforatum. Part 1. Isolation of 13, II8- biapigenin. Planta Med. 1987;53:216–7.CrossRefGoogle Scholar
  5. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol. 1994;7:57–9.CrossRefGoogle Scholar
  6. Bombardelli E, Morazzoni P. Hypericum perforatum. Fitoterpia. 1995;66:43–68.Google Scholar
  7. Bombardelli E, Morazzoni P, Riva A. IDN 5491 (Hyperforin trimethoxybenzoate): A new antidepressive drug. Eur Neuropsychopharmacol 2002;12:240.CrossRefGoogle Scholar
  8. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, Keller M, Groschup MH, Vogelgesang S. St. John’s Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer’s disease mouse model-role of P-glycoprotein. Brain Pathol. 2014;24:18–24.CrossRefPubMedGoogle Scholar
  9. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris: Lavoisier Publishing; 1995.Google Scholar
  10. Butterweck V. Mechanism of action of St John’s Wort in depression. CNS Drugs. 2003;17:539–62.CrossRefPubMedGoogle Scholar
  11. Butterweck V, Petereit F, Winterhoff H. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med. 1998;64:291–4.CrossRefPubMedGoogle Scholar
  12. Butterweck V, Jurgenliemk G, Nahrstedt A, Winthehoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Thieme: Fachzeitschriften: Planta Medica 2000;66:3–6.CrossRefPubMedGoogle Scholar
  13. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A, De Sarro G, Caputi AP. Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry. 2001a;34:8–10.CrossRefGoogle Scholar
  14. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, De Sarro G, Caputi A. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry. 2001b;34:45–9.CrossRefPubMedGoogle Scholar
  15. Can OD, Ozkay UD. Effects of Hypericum montbretti extract on the central nervous system and involvement of GABA (A)/Benzodiazepine receptors in its pharmacological activity. Phytother Res. 2012;26:1695–700.CrossRefPubMedGoogle Scholar
  16. Can OD, Ismail IB, Oztürk Y, Oztürk N, Potoğlu-Erkara I, Sagratini G, Ricciutelli M, Vittori S, Maggi F. New antidepressant drug candidate: Hypericum montbretti extract. Nat Prod Res. 2011a;25:1469–72.CrossRefPubMedGoogle Scholar
  17. Can OD, Oztürk Y, Ozkay UD. Effects of insulin and St. John’s Wort treatments on anxiety, locomotory activity, depression, and active learning parameters of streptozotocin-diabetic rats. Planta Med. 2011b;77:1970–6.CrossRefPubMedGoogle Scholar
  18. Centurião FB, Braga A, Machado FR, Tagliari B, Müller LG, Kolling J, Gv P, Wyse AT, Rates SM. Study of antidepressant-like activity of an enriched phloroglucinol fraction obtained from Hypericum caprifoliatum. Pharm Biol. 2014;52:105–10.CrossRefPubMedGoogle Scholar
  19. Chang Y, Wang SJ. Hypericin, the active component of St. John’s wort, inhibits glutamate release in the rat cerebrocortical synaptosomes via a mitogen-activated protein kinase-dependent pathway. Eur J Pharmacol. 2010;634:53–61.CrossRefPubMedGoogle Scholar
  20. Davidson JRT, Gadde KM, Fairbank JA, et al. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807.CrossRefGoogle Scholar
  21. Eckert GP, Muller WE. Effects of hyperforin on the fluidity of brain membranes. Pharmacopsychiatry. 2001;34:22–5.CrossRefGoogle Scholar
  22. Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry. 1998;31:2–6.CrossRefPubMedGoogle Scholar
  23. Findling RL, McNamara NK, O’Riordan MA, Reed MD, Demeter CA, Branicky LA, Blumer JL. An open-label pilot study of St. John’s wort in juvenile depression. J Am Acad Child Adolesc Psychiatry. 2003;42:908–14.CrossRefPubMedGoogle Scholar
  24. Flausino OA Jr, Zangrossi H Jr, Salgado JV, Viana MB. Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats. Pharmacol Biochem Behav. 2002;71:251–7.CrossRefPubMedGoogle Scholar
  25. Gastpar M, Singer A, Zeller K. 2005. Efficacy and tolerability of Hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. 2005;38:78–86.CrossRefPubMedGoogle Scholar
  26. Gastpar M, Singer A, Zeller K. 2006. Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006;39:66–75.CrossRefPubMedGoogle Scholar
  27. Gómez del Rio MA, Sánchez-Reus MI, Iglesias I, Pozo MA, García-Arencibia M, Fernández-Ruiz J, García-García L, Delgado M, Benedí J. Neuroprotective properties of standardized extracts of Hypericum perforatum on rotenone model of Parkinson’s disease. CNS Neurol Disord Drug Targets. 2013;12:665–79.CrossRefPubMedGoogle Scholar
  28. Grundmann O, Kelber O, Butterweck V. Effects of St. John’s wort extract and single constituents on stress-induced hyperthermia in mice. Planta Med. 2006;72:1366–71.CrossRefPubMedGoogle Scholar
  29. Gunther RT. The Greek herbal of dioscorides. New York: Hafner Pub Co. 1968.Google Scholar
  30. Hansgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extracts LI 160. J Geriatr Psychiatry Neurol. 1994;7:15–8.CrossRefGoogle Scholar
  31. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol. 1994;7:24–8.CrossRefGoogle Scholar
  32. Hoffmann J, Kühl ED. Therapy of depressive states with hypericin. ZFA (Stuttgart) 1979;55:776–782.Google Scholar
  33. Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr Psychiatry Neurol. 1994;1:12–4.CrossRefGoogle Scholar
  34. Husain GM, Chatterjee SS, Singh PN, Kumar V. Beneficial effect of Hypericum perforatum on depression and anxiety in a type 2 diabetic rat model. Acta Pol Pharm. 2011;68:913–8.PubMedGoogle Scholar
  35. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci. 2001;68:1593–605.CrossRefPubMedGoogle Scholar
  36. Johnson D, Ksciuk H, Woelk H, Sauerwein-Giese E, Frauendorf A. Effects of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers. J Geriatr Psychiatry Neurol. 1994;7:44–6.CrossRefGoogle Scholar
  37. Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci Lett. 1999;262:199–202.CrossRefPubMedGoogle Scholar
  38. Kasper S. Treatment of seasonal affective disorder (SAD) with Hypericum extract. Pharmacopsychiatry. 1997;30:89–93.CrossRefPubMedGoogle Scholar
  39. Kiasalari Z, Baluchnejadmojarad T, Roghani M. Hypericum perforatum Hydroalcoholic extract mitigates motor dysfunction and is neuroprotective in Intrastriatal 6-Hydroxydopamine rat model of Parkinson’s disease. Cell Mol Neurobiol. 2016;36:521–30.CrossRefPubMedGoogle Scholar
  40. Kitanov G. Determination of the absolute configuration of catechins isolated from Hypericum perforatum. Farmatsiya (Sofia) 1983;33:19–22.Google Scholar
  41. Koget TA. Determination of the amount of quercitrin in Hypericum perforatum. Khim Prir Soedin. 1972;(2):242–3.CrossRefGoogle Scholar
  42. Kumar A, Singh A. Protective effect of St. John’s wort (Hypericum perforatum) extract on 72-hour sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Planta Med. 2007;73:1358–64.CrossRefPubMedGoogle Scholar
  43. Kumar V, Singh PN, Jaiswal AK, Bhattacharya SK. Antidepressant activity of Indian Hypericum perforatum Linn in rodents. Indian J Exp Biol. 1999;37:1171–6.PubMedGoogle Scholar
  44. Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J Exp Biol. 2000;38:36–41.PubMedGoogle Scholar
  45. Kumar V, Singh PN, Bhattacharya SK. Anti-stress activity of Indian Hypericum perforatum L. Indian J Exp Biol. 2001;39:344–9.PubMedGoogle Scholar
  46. Laakmann G, Schule C, Baghai T, Kieser M. St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31:54–9.CrossRefPubMedGoogle Scholar
  47. Leung AY, Foster S. Encyclopedia of common natural ingredients used in food, drugs and cosmetics. 2nd. ed. New York: Wiley; 1996.Google Scholar
  48. Liu J, Fang Y, Wei Z, Yang X, Zeng L. Synergic antidepressive effect of quercetin and Hypericum perforatum extract in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42:615–9.PubMedGoogle Scholar
  49. Maisenbacher P, Kovar KA. Adhyperforin - a homologue of hyperforin from Hypericum perforatum. Planta Med. 1992;58:291–3.CrossRefPubMedGoogle Scholar
  50. Mathis C, Ourisson G. Etude Chimio-taxonomique du genre Hypericum. Phytochemistry. 1964;3:379.CrossRefGoogle Scholar
  51. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci. 2004;75:1021–7.CrossRefPubMedGoogle Scholar
  52. Mukherjee KP, Suresh B, Verpoorte R. {CNS} active potentials of some Hypericum species of India. Phytomedicine. 2001;8:331–7.CrossRefPubMedGoogle Scholar
  53. Müldner H, Zöller M. Antidepressive effect of a Hypericum extract standardized to an active hypericine complex. Biochemical and clinical studies. Arzneimittelforschung. 1984;34:918–20.PubMedGoogle Scholar
  54. Muller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30:102–7.CrossRefPubMedGoogle Scholar
  55. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 1998;1:16–21.CrossRefGoogle Scholar
  56. Muller WE, Singer A, Wonnemann M. Hyperforin-antidepressant activity by a novel mechanism of action. Pharmacopsychiatry. 2001;34:98–102.CrossRefGoogle Scholar
  57. Muruganandam AV, Ghosal S, Battacharya SK. The role of xanthones in the antidepressant activity of Hypericum perforatum involving dopaminergic and serotonergic systems. Biogenic Amines. 2000;15:553–67.Google Scholar
  58. Muruganandam AV, Bhattacharya SK, Ghosal S. Antidepressant activity of hyperforin conjugates of the St. John’s wort, Hypericum perforatum Linn.: an experimental study. Indian J Exp Biol. 2001;39:1302–4.PubMedGoogle Scholar
  59. Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 1999;816:358–63.CrossRefPubMedGoogle Scholar
  60. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health care professionals. London: The Pharmaceutical Press; 1996.Google Scholar
  61. Niederhofer H. St. John’s wort may diminish methylphenidate’s efficacy in treating patients suffering from attention deficit hyperactivity disorder. Med Hypotheses. 2007;68:1189.CrossRefPubMedGoogle Scholar
  62. Niederhofer H. St John’s wort treating patients with autistic disorder. Phytother Res. 2009;23:1521–3.CrossRefPubMedGoogle Scholar
  63. Niederhofer H. St. John’s wort may improve some symptoms of attention-deficit hyperactivity disorder. Nat Prod Res. 2010;24:203–5.CrossRefPubMedGoogle Scholar
  64. Nöldner M, Schötz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med. 2002;68:577–80.CrossRefPubMedGoogle Scholar
  65. Okpanyi SN, Weischer ML. Animal experiments on the psychotropic action of a Hypericum extract. Arzneimittelforschung. 1987;37:10–3.PubMedGoogle Scholar
  66. Öztürk Y, Aydin S, Beis R, Baser KHC, Berberoglu H. Effects of Hypericum calycinum L. extract on the central nervous system in mice. Phytother Res. 1996;10:700–2.CrossRefGoogle Scholar
  67. Perovic S, Muller WE. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung. 1995;45:1145–8.PubMedGoogle Scholar
  68. Pongiya UD, Kandanath BM, Rao YR, RafiqKhan M. Protective effect of Hypericum hookerianum in reversing haloperidol induced schizophrenia-like behaviors in Swiss albino mice. Asian J Biomed Pharm Sci. 2014;4(33):14–23.CrossRefGoogle Scholar
  69. Rasmussen PS. John’s wort-a review of its use in depression. Australian J Med Herbalism. 1998;10:8–13.Google Scholar
  70. Sánchez-Mateo CC, Bonkanka CX, Prado B, Rabanal RM. Antidepressant activity of some Hypericum reflexum L. fil. Extracts in the forced swimming test in mice. J Ethnopharmacol. 2007;112:115–21.CrossRefPubMedGoogle Scholar
  71. Sánchez-Mateo CC, Bonkanka CX, Rabanal RM. Hypericum grandifolium Choisy: a species native to Macaronesian Region with antidepressant effect. J Ethnopharmacol. 2009;121:297–303.CrossRefPubMedGoogle Scholar
  72. Scheggi S, Marandino A, Del Monte D, De Martino L, Pelliccia T, Del Rosario Fusco M, Petenatti EM, Gambarana C, De Feo V. The protective effect of Hypericum connatum on stress-induced escape deficit in rat is related to its flavonoid content. Pharm Biol. 2016;54:1782–92.CrossRefPubMedGoogle Scholar
  73. Schmidt U, Sommer H. St. John’s wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved. Fortschr Med. 1993;111:339–42.PubMedGoogle Scholar
  74. Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Clin Psychopharmacol. 2000;15:61–8.CrossRefGoogle Scholar
  75. Seifritz E, Hatzinger M, Holsboer-Trachsler E. Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode - a subgroup analysis. Int J Psychiatry Clin Pract. 2016;20:126–32.CrossRefPubMedPubMedCentralGoogle Scholar
  76. Shanmugam M, Shanmugasundaram KK. Biochemical and phytochemical characterization of Hypericum mysorense - an antidepressant unexploited medicinal plant of Nilgiris biosphere. Ancient Sci Life. 2009;29:29–32.Google Scholar
  77. Simmen U, Bobirnac I, Ullmer C, Lubbert H, Berger Buter K, Schaffner W, Schoeffter P. Antagonist effect of pseudohypericin at CRF1 receptors. Eur J Pharmacol. 2003;548:251–6.CrossRefGoogle Scholar
  78. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of a hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neurol. 1994;7:9–11.CrossRefGoogle Scholar
  79. Sticher O. Plant mono-, di- and sesquiterpenoids with pharmacological or therapeutical activity. In: Wagner H, Wolff P, editors. New natural products and plant drugs with pharmacological, biological or therapeutical activity. Springer: New York; 1977.Google Scholar
  80. Taylor LH, Kobak KA. An open-label trial of St. John’s wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000;61:575–8.CrossRefPubMedGoogle Scholar
  81. Thiede HM, Walper A. Inhibition of MAO and COMT by Hypericum extracts and hypericin. J Geriatr Psychiatry Neurol. 1994;7:54–6.CrossRefGoogle Scholar
  82. Tian J, Zhang F, Cheng J, Guo S, Liu P, Wang H. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci Rep. 2014;4:5632.CrossRefPubMedPubMedCentralGoogle Scholar
  83. Upton R, editor. St. John’s wort monograph. Santa Cruz: American Herbal Pharmacopoeia; 1997.Google Scholar
  84. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol. 1994;1:19–23.CrossRefGoogle Scholar
  85. Wang D, Bai J, Sun F, Yang D. Chemical constituents and antidepressant activity of the new species Hypericum enshiense occurring in China. Phytomedicine. 2010a;17:410–3.CrossRefPubMedGoogle Scholar
  86. Wang Y, Shi X, Qi Z. Hypericin prolongs action potential duration in hippocampal neurons by acting on K+ channels. Br J Pharmacol. 2010b;159(7):1402.CrossRefPubMedPubMedCentralGoogle Scholar
  87. Weber W, Vander Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J. Hypericum perforatum (St. John’s wort) for attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 2008;299:2633–41.CrossRefPubMedPubMedCentralGoogle Scholar
  88. Wenzel E. On the therapy of depressive states with hypericin (preliminary results with the experimental preparation Hyp. No 1). Z Gesamte Inn Med. 1959;14:054–7.PubMedGoogle Scholar
  89. Wheatley D. LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients: a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30:77–80.CrossRefPubMedGoogle Scholar
  90. Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U. Treatment of depressive symptoms with a high concentration Hypericum preparation. A multicenter, placebo-controlled double-blind study. Fortschr Med. 1995;13:404–8.Google Scholar
  91. Wonnemann M, Singer A, Müller WE. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John’s wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology. 2000;23:188–97.CrossRefPubMedGoogle Scholar
  92. Wonnemann M, Singer A, Siebert B, Müller WE. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John’s wort. Pharmacopsychiatry. 2001;34:148–51.CrossRefGoogle Scholar
  93. Yaşar SN, Can OD, Oztürk N, Sagratini G, Ricciutelli M, Vittori S, Maggi F. Central nervous system activities of Hypericum origanifolium extract via GABAergic and opioidergic mechanisms. Phytother Res. 2013;27:877–84.CrossRefPubMedGoogle Scholar
  94. Zanoli P, Rivasi M, Baraldi C, Baraldi M. Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 2002;13:645–51.CrossRefPubMedGoogle Scholar
  95. Zheleva-Dimitrova D, Nedialkov P, Momekov G. Benzophenones from Hypericum elegans with antioxidant and acetylcholinesterase inhibitory potential. Pharmacogn Mag. 2013;9:1–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Amritpal Singh Saroya
    • 1
  • Jaswinder Singh
    • 2
  1. 1.Herbal ConsultantMohaliIndia
  2. 2.Department of PharmacologySri Guru Ram Das Institute of Medical ScienceAmritsarIndia

Personalised recommendations